Women's Health MRI

For patients with triple-negative breast cancer being treated with neoadjuvant chemotherapy and immunotherapy, MRI demonstrated a 94.3 percent sensitivity for predicting pathologic complete response, according to a new study.

In addition to offering a variety of AI features, the Magnetom Flow 1.5T MRI system reportedly facilitates a 56 percent reduction in annual energy consumption in comparison to previous MRI scanners.

Employing a 77-second scan time for obtaining ultrafast breast MRI views, researchers found a 92.1 percent AUC for differentiating between benign and malignant lesions, according to new prospective study.

Catch up on the most well-viewed MRI content from 2025.

Catch up on the most well-viewed radiology content from 2025.

The cloud-based Brain Mets software reportedly provides accelerated detection, measurement and tracking of metastatic brain lesions based on routine brain MRI sequences.

Catch up on the most well-viewed video interviews from 2025.

The multi-directional diffusion-weighted imaging (DWI) sequence reportedly bolsters small stroke detection and infarct differentiation for portable MRI of the brain.

Catch up on the top AI-related news and research in radiology over the past month.

For T3-T4 rectal cancer staging, a new study showed that optimal photon-counting CT offered an AUC range between 80 and 86 percent in comparison to an AUC range between 78 and 88 percent for rectal MRI.

Incorporating mpMRI radiomics, clinical characteristics, deep learning and pathomic features, a multimodal model offered 82 percent and 87 percent AUCs for predicting overall survival outcomes at five years and seven years, respectively, for women treated with neoadjuvant chemotherapy for breast cancer.

Multivariable analysis from a new study revealed that those with low right ventricular global longitudinal strain were 16 percent more likely to suffer heart failure.

Ultrasound-derived fat fraction assessment offered higher AUCs for differentiating mild, moderate and severe hepatic steatosis in comparison to established noninvasive measures of metabolic dysfunction-associated steatosis liver disease (MASLD), according to new multicenter research.

Catch up on the most-well viewed radiology content in October 2025.

For patients with esophageal cancer, preoperative MRI demonstrated an average AUC above 94 percent for detecting tracheal invasion in contrast to an AUC range between 52.9 and 70.6 percent for CT, according to a recently published study.

Catch up on the most-well viewed MRI content in October 2025.

Pre-op breast MRI was associated with a 12.5 percent reduced 5-year cumulative incidence of recurrence for patients who underwent surgery for hormone receptor-negative cancer, according to newly published research.

In a recent interview, Deepa Sheth, M.D., discussed the rising incidence of breast cancer, key considerations in supplemental imaging for women with dense breasts and use of the CIVIE RadPod platform to facilitate consistent quality and imaging reads by fellowship-trained breast radiologists.

Deep learning assessment of MRI offered a 24 percent higher sensitivity than radiologist interpretation for detecting lymph node metastasis in patients with colorectal cancer, according to a new meta-analysis.

The iron-based brain MRI contrast agent Ferabright (ferumoxytol injection) is indicated for adult patients with known or suspected malignant neoplasms.

While dynamic contrast enhanced breast MRI may help reduce biopsies for suspicious calcifications on mammograms, quantitative MRI features and diffusion-weighted imaging (DWI) may not provide additional diagnostic benefit in these cases, according to a new study.

Catch up on the top radiology content of the past week.

Women who had an MRI prior to undergoing surgery for newly diagnosed breast cancer were 18 percent more likely to have a mastectomy, according to newly published research.

Catch up on the top radiology content of the past week.

For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.